Advertisement

Use of hydroxychloroquine to control immune response and hypercoagulability in patients with primary antiphospholipid syndrome

      Dear Editor,

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Turiel M.
        • Sarzi-Puttini P.
        • Peretti R.
        • et al.
        Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.
        Stroke. 2005; 36: 1490-1494
        • Finazzi G.
        • Marchioli R.
        • Brancaccio V.
        • et al.
        A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
        J Thromb Haemostasis: JTH. 2005; 3: 848-853
        • Belizna C.
        Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome.
        Autoimmun Rev. 2015; 14: 358-362
        • Ruiz-Irastorza G.
        • Cuadrado M.J.
        • Ruiz-Arruza I.
        • et al.
        Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.
        Lupus. 2011; 20: 206-218
        • Hsu C.Y.
        • Lin Y.S.
        • Su Y.J.
        • et al.
        Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study.
        Rheumatology (Oxford). 2017; 56: 2212-2221
        • Petri M.
        Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.
        Lupus. 1996; 5: S16-S22
        • Ruiz-Irastorza G.
        • Egurbide M.V.
        • Pijoan J.I.
        • et al.
        Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.
        Lupus. 2006; 15: 577-583
        • Wallace DJ.
        Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?.
        Arthritis Rheumatism. 1987; 30: 1435-1436
        • Tobaldini L.Q.
        • Arantes F.T.
        • Saraiva S.D.S.
        • et al.
        Circulating levels of tissue factor and the risk of thrombosis associated with antiphospholipid syndrome.
        Thromb Res. 2018; 171: 114-120
        • Saraiva Sda S.
        • Custódio I.F.
        • Mazetto Bde M.
        • et al.
        Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response.
        Thromb Res. 2015; 136: 1174-1178